Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and suppress expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Anagrelide is an active ingredient of these brands:
While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.